Bernard Vandercam
- Infectious Diseases top 2%
- HIV/AIDS drug development and treatment 4
- Antifungal resistance and susceptibility 2
- Antimicrobial Resistance in Staphylococcus 2
- Clinical Biochemistry top 2%
- Epidemiology top 10%
- Mycobacterium research and diagnosis 3
- Virology top 10%
- HIV Research and Treatment 3
-
- Antibiotic Resistance in Bacteria 2
-
- Cancer Treatment and Pharmacology 2
- Neutropenia and Cancer Infections 2
Bernard Vandercam
17 papers receiving 723 citations
Peers
Comparison fields: 5 of 74
- Infectious Diseases 563
- Clinical Biochemistry 196
- Epidemiology 329
- Virology 42
- Molecular Medicine 31
Countries citing papers authored by Bernard Vandercam
This map shows the geographic impact of Bernard Vandercam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernard Vandercam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernard Vandercam more than expected).
Fields of papers citing papers by Bernard Vandercam
This network shows the impact of papers produced by Bernard Vandercam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernard Vandercam. The network helps show where Bernard Vandercam may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Bernard Vandercam, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 1 | |
| 2 | 2012 | 6 | |
| 3 | 2009 | 7 | |
| 4 | 2006 | 6 | |
| 5 | Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy. | 2005 | 11 |
| 6 | 2005 | 34 | |
| 7 | Prospective collection of data on the prevalence of transmitted resistance in newly diagnosed HIV-infected individuals in Belgium in 2003 | 2004 | 0 |
| 8 | 1999 | 38 | |
| 9 | 1999 | 46 | |
| 10 | 1998 | 183 | |
| 11 | Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients | 1996 | 5 |
| 12 | 1996 | 50 | |
| 13 | 1995 | 250 | |
| 14 | HIV infection and rape. | 1992 | 3 |
| 15 | 1989 | 7 | |
| 16 | 1987 | 63 | |
| 17 | Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study. | 1987 | 60 |
| 18 | 1985 | 2 |
About Bernard Vandercam
Bernard Vandercam is a scholar working on Virology, Infectious Diseases, Molecular Medicine, Emergency Medicine and Clinical Biochemistry, having authored 18 papers that have together received 772 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (4 papers), HIV Research and Treatment (3 papers), Mycobacterium research and diagnosis (3 papers), Antifungal resistance and susceptibility (2 papers), Antibiotic Resistance in Bacteria (2 papers), Cancer Treatment and Pharmacology (2 papers), Antimicrobial Resistance in Staphylococcus (2 papers) and Neutropenia and Cancer Infections (2 papers). The work is most often cited by research in Infectious Diseases (563 citations), Clinical Biochemistry (196 citations), Epidemiology (329 citations), Virology (42 citations) and Molecular Medicine (31 citations). Bernard Vandercam has collaborated with scholars based in Belgium, Netherlands and United Kingdom. Frequent co-authors include Michel Delmée, Jean‐Luc Gala, Pascal Vannuffel, G. Wauters, J. Gigi, H Ezzedine, V. Avesani, J. L. Michaux, Éric Goffin and Laurence Collette. Their work appears in journals such as Clinical Infectious Diseases, Clinical Nephrology, Journal of Clinical Microbiology, European Journal of Clinical Microbiology & Infectious Diseases and Research in Microbiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.